Connect your AI

Opus Genetics IRD Retained Earnings

Retained Earnings at other companies

AbbVieABBV

-$17.87B-87.6%

MeiraGTx Holdings plcMGTX

-$862.54M-16.2%

4D Molecular TherapeuticsFDMT

-$785.06M-25.8%

Opko HealthOPK

-$2.35B-10.0%

Kodiak Sciences IncKOD

-$1.62B-16.6%

Regeneron PharmaceuticalsREGN

$36.42B+12.5%

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's retained earnings?: Opus Genetics (IRD) reported retained earnings of -$254.12M in Q1 2026.
How has Opus Genetics's retained earnings changed year-over-year?: Opus Genetics's retained earnings decreased by 72.6% year-over-year, from -$147.19M to -$254.12M.
What is the long-term trend for Opus Genetics's retained earnings?: Over 5 years (2020 to 2025), Opus Genetics's retained earnings has grown at a 42.0% compound annual growth rate (CAGR), from -$32.68M to -$188.59M.
What does retained earnings mean?: Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.